logo-2GrowBlox Sciences, Inc is a development-stage company that offers cultivating and processing solutions to medical marijuana businesses. These solutions are primarily the proprietary technologies that the company itself has developed, and GrowBlox Sciences intends to implement these in Nevada through its state-level partners.

The company was founded in 2001 and first operated as Flagstick Ventures, Inc. It underwent various changes in business and name: in 2004, it became the Diabetic Treatment Centers of America, Inc, and in 2008, it changed to Signature Exploration and Production Corp. Finally, in April 2014, it became GrowBlox Sciences, Inc.

The company is now being traded in the OTC markets under the symbol GBLX. Its value is estimated at USD 22.41 M.

GrowBlox Sciences’ technologies cater to various aspects of the marijuana cultivation process. One of the company’s major technologies is the GrowBlox Cannabis Grow Chamber, an indoor plant-growing chamber equipped with climate and environment controls. The company also has the InCUBEator Cannabis Propagation Chamber, designed to ensure the consistency of cannabis cultivation through the tissue culture method.

Another solution developed by GrowBlox is the ConversionLAB, which is used in the extraction of the medicinal compounds of cannabis, utilizing CO2 to produce clean extracts. Finally, for the drying and curing of marijuana, there is the CureBLOX Cannabis Drying System. This process follows an algorithm that regulates temperature and humidity and thus makes the product pathogen-free.

In addition, GrowBlox is one of the leading companies that process state and local licenses in places where medical cannabis programs are established. The company does this with its specialists in application requests such as compliance, sales plans, packaging, branding, and security.

The management team at GrowBlox Sciences, Inc comprises CEO and Chairman Craig M. Ellins, CFO and Chief Accounting Officer Steven W. Weldon, and Chief Science Officer Dr. Andrea Small-Howard.


Yahoo! Finance: GBLX News

Latest Financial News for GBLX

GB Sciences Using AI Technology in Plant-Based Drug Discovery Research

Biotech innovator GB Sciences has launched a drug discovery platform using AI technology that can identify and predict the efficacy of combinations of novel active ingredients from plants.LAS VEGAS, NV / ACCESSWIRE / June 29, 2021 / GB Sciences (OTCQB:GBLX) is leading the way in cutting-edge biopharmaceutical research with its novel AI-accelerated drug discovery platform-PhAROS™ - Phytomedical Analytics for Research Optimization at Scale.

Gary Herman Joins GB Sciences' Subsidiary GbS Global Biopharma as Advisory Director

LAS VEGAS / ACCESSWIRE / June 22, 2021 / GB Sciences, Inc. (OTCQB:GBLX) announces that long-term investor Gary Herman has joined GbS Global Biopharma, Inc.

GB Sciences' Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President

The UWC also retains John Poss as Chairman and CEO of GB Sciences, Inc.LAS VEGAS, NV / ACCESSWIRE / June 17, 2021 /Dr.

GB Sciences Featured & Speaking at the SACHS Associates' 4th Annual Neuroscience Innovation Forum

LAS VEGAS, NV / ACCESSWIRE / April 27, 2021 / GB Sciences (GBS), Inc. (OTCQB:GBLX), a leading phytomedicine research and biopharmaceutical development company, will be featured during the SPOTLIGHT SHOWCASE at the SACHS Associates' 4th Annual Neuroscience Innovation Forum (NIF) for Business Development, Licensing & Investment from April 28 to April 30.

GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals

Purisys will supply ultra-high purity cannabinoids for use in GB Sciences' cannabinoid-containing, optimized therapeutic mixtures (OTM).LAS VEGAS, NV / ACCESSWIRE / April 20, 2021 / GB Sciences, Inc.